Skin Cancer

The information below is intended for use by health care providers only. Please consult with your health care provider for more information about clinical trials.

Circulating tumor DNA exposure in peripheral blood using a novel process: A feasibility study

The objective of this study is to test the feasibility of the detection of tumor DNA of a variety of tumors in peripheral blood using a novel process for the detection of circulating tumor DNA (ctDNA).

Study Details

  • Study Site/Tumor Location: Colon or rectal, pancreatic, gastric, or hepatocellular carcinoma hepatocellular carcinoma, non-small cell lung cancer, bladder cancer, melanoma
  • Study Location: Miami Valley Hospital
  • Ages eligible for study: 18 years and older
  • Genders eligible for study: Both
  • Principal Investigator: Dr. Jim Ouellette

Study Contact Information

Performance of the DecisionDx-Melanoma Gene Expression Profile Test for Prognosis of Recurrence Risk

To further evaluate the performance of DecisionDx-Melanoma in specific cohorts of subjects with primary cutaneous melanoma, including subjects with thin tumors less than 1mm in thickness with subsequent metastasis, and those with tumors identified as substage IIA, IIB, IIC, IIIA, IIIB, or IIIC.

Study Details

  • Study Site/Tumor Location: Melanoma
  • Study Location: Miami Valley Hospital
  • Ages eligible for study: 18 years and older
  • Genders eligible for study: Both
  • Principal Investigator: Dr. Jim Ouellette

Study Contact Information

S1616 Nivolumab w/ Ipilimumab or Ipilimumab Alone in Advanced Melanoma Refractory to an Anti-PD1 or Anti-PD-L1 Agent

Study Details

  • Study Site/Tumor Location: Melanoma
  • Study Location: All Premier
  • Ages eligible for study: 18 years and older
  • Genders eligible for study: Both
  • Principal Investigator: Dr. Gross
  • Other Physicians who can consent: Dr. Bane, Dr. Cheruvu, Dr. Ditzel, Dr. Guy, Dr. Jilani, Dr. Kathula, Dr. Koduri, Dr. Marinella, Dr. Miller, Dr. Okoye, Dr. Rajsheker, Dr. Romer, Dr. Sabagh, Dr. Setzkorn, Dr. Sheth, Dr. Steinmetz

Study Contact Information

S1801 Adjuvant vs. Neoadjuvant MK-3475 (Pembrolizumab) for Clinically Detectable Stage III-IV High-Risk Melanoma

Study Details

  • Study Site/Tumor Location: Melanoma
  • Study Location: All Premier
  • Ages eligible for study: 18 years and older
  • Genders eligible for study: Both
  • Principal Investigator: Dr. Gross
  • Other Physicians who can consent: Dr. Bane, Dr. Cheruvu, Dr. Ditzel, Dr. Guy, Dr. Jilani, Dr. Kathula, Dr. Koduri, Dr. Marinella, Dr. Miller, Dr. Okoye, Dr. Rajsheker, Dr. Romer, Dr. Sabagh, Dr. Setzkorn, Dr. Sheth, Dr. Steinmetz

Study Contact Information